当前位置: X-MOL 学术J. Hepatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation
Journal of Hepatology ( IF 26.8 ) Pub Date : 2020-05-01 , DOI: 10.1016/j.jhep.2019.12.004
Zechuan Zhang 1 , Xiaoliang Xu 2 , Wenfang Tian 3 , Runqiu Jiang 3 , Yijun Lu 1 , Qikai Sun 3 , Rao Fu 3 , Qifeng He 3 , Jincheng Wang 3 , Yang Liu 3 , Hailong Yu 3 , Beicheng Sun 4
Affiliation  

BACKGROUND & AIMS Non-alcoholic steatohepatitis (NASH) is associated with dysregulation of lipid metabolism and hepatic inflammation. The causal mechanism underlying NASH is not fully elucidated. We aim to investigate the role of β-arrestin1 (ARRB1) in the progression of NASH. METHODS Human liver tissues from patients with NASH and control subjects were obtained to evaluate ARRB1 expression. NASH models were established in ARRB1 knockout and wild type mice fed high-fat diet (HFD) for 26 weeks or methionine/choline deficient (MCD) diet for 6 weeks. RESULTS ARRB1 expression was diminished in NASH patient liver samples. Moreover, diminished ARRB1 levels were detected in mice NASH models. ARRB1 deficiency accelerated steatohepatitis development in HFD-/MCD diet-fed mice accompanied by upregulation of lipogenic genes and downregulation of β-oxidative genes. Intriguingly, ARRB1 was found to interact with GDF15 and facilitated the transportation of GDF15 precursor (pro-GDF15) to Golgi apparatus for cleavage and maturation. Treatment with recombinant GDF15 ablated the lipid accumulation in the presence of ARRB1 deletion in vitro and in vivo. Re-expression of ARRB1 in the NASH models ameliorated the liver disease, and the effect was greater in the presence of pro-GDF15 overexpression. In contrast, the effect of pro-GDF15 overexpression alone was impaired in ARRB1-deficient mice. In addition, the severity of liver disease in patients with NASH was negatively correlated with ARRB1 expression. CONCLUSION ARRB1 acts as a vital regulator in the development of NASH via facilitating GDF15's translocation to the Golgi apparatus and subsequent maturation. ARRB1 thus is a potential therapeutic target for the treatment of NASH.

中文翻译:

ARRB1 通过促进 GDF15 成熟抑制非酒精性脂肪性肝炎进展

背景和目的 非酒精性脂肪性肝炎 (NASH) 与脂质代谢失调和肝脏炎症有关。NASH 背后的因果机制尚未完全阐明。我们旨在研究 β-arrestin1 (ARRB1) 在 NASH 进展中的作用。方法 获取 NASH 患者和对照受试者的人肝组织以评估 ARRB1 的表达。NASH 模型在 ARRB1 基因敲除小鼠和高脂肪饮食 (HFD) 26 周或蛋氨酸/胆碱缺乏 (MCD) 饮食 6 周的野生型小鼠中建立。结果 在 NASH 患者肝脏样本中 ARRB1 表达减少。此外,在小鼠 NASH 模型中检测到 ARRB1 水平降低。ARRB1 缺乏加速了 HFD-/MCD 饮食喂养小鼠脂肪性肝炎的发展,伴随着脂肪生成基因的上调和 β-氧化基因的下调。有趣的是,发现 ARRB1 与 GDF15 相互作用并促进 GDF15 前体(pro-GDF15)运输到高尔基体进行裂解和成熟。在体外和体内存在 ARRB1 缺失的情况下,用重组 GDF15 处理可以消除脂质积累。在 NASH 模型中 ARRB1 的重新表达改善了肝脏疾病,并且在 pro-GDF15 过表达的情况下效果更好。相比之下,仅在 ARRB1 缺陷小鼠中,pro-GDF15 过表达的效果就会受损。此外,NASH患者肝脏疾病的严重程度与ARRB1表达呈负相关。结论 ARRB1 通过促进 GDF15 向高尔基体的易位和随后的成熟,在 NASH 的发展中起到重要的调节作用。因此,ARRB1 是治疗 NASH 的潜在治疗靶点。
更新日期:2020-05-01
down
wechat
bug